Summary Acute exacerbations (AE) can be recurrent problems for patients with moderateto-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that !50% of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis * This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction
Chronic obstructive pulmonary disease (COPD) is a substantial public health burden, associated with a high incidence of morbidity and mortality and affecting 24 million people in the USA and approximately 7% of Europeans. 1e3 The predicted number of affected people in Asia Pacific region is even higher (>55 million). 4 The progressive course of COPD is accelerated by acute exacerbations (AE-COPD), which are episodes of worsening of symptoms, which are the most frequent cause of hospitalisations and death among COPD patients. 5e8 Health status of hospitalised patients with severe exacerbations declines more rapidly after the second admission with risk of mortality remaining high for approximately 90 days after every severe episode. 7 Therefore, treatments that reduce exacerbation frequency will have a significant impact on health status, survival and reduce the economic burden of COPD. 9, 10 Treatment with inhaled corticosteroids, long-acting anticholinergics or beta-agonists appears to have modest but significant effects on preventing or reducing subsequent moderate and severe exacerbations in COPD patients. 11e14 However, improvements in the treatment of stable COPD are needed to further decrease exacerbations and improve outcomes. Evidence based on sputum culture results suggests that bacterial infection may be responsible for around half of AE-COPD, 15 with a clear relationship being demonstrated between sputum purulence and the presence of bacteria. 16, 17 For this reason, current guidelines recommend acute antibiotic therapy for patients with more severe symptoms of AE-COPD, with treatment typically lasting for 5e7 days. 18e21 In particular, guidelines issued by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Joint Task Force of the European Respiratory Society and the European Society for Clinical Microbiology and Infectious Diseases advocate antibiotic use for those with Anthonisen type I (worsening dyspnoea with increased sputum volume and purulence) or type II (change in any two of these symptoms, particularly if one of these symptoms is increase in sputum purulence) episodes, 18, 20, 21 while the Canadian Thoracic Society suggests that antibiotics are beneficial for severe purulent AE-COPD (i.e. new increased expectoration of mucopurulent sputum and dyspnoea). 19 Nevertheless, while such treatment has been shown to reduce the risk of subsequent exacerbations, relapse is common. 22 Failure may be related to inadequate antibiotic efficacy, which through incomplete resolution of the initial exacerbation and persistent bacterial infection is likely to influence risk of relapse. 23e27 Indeed, confirmed bacterial eradication following antibiotic therapy has been shown to be associated with higher clinical cure rates in patients with AE-COPD. 28 Effective treatment of the acute exacerbation and reducing the risk of a subsequent bacterial exacerbation are thus important therapeutic goals for antimicrobial treatment in COPD that may improve, in addition to other conventional treatments (e.g. long-acting bronchodilators and inhaled corticosteroids), the patients' quality of life.
The rate at which exacerbations occur appears to reflect an independent susceptibility phenotype. 5, 29 Furthermore, exacerbations appear to cluster together, with some patients remaining at high risk for recurrent exacerbation for some weeks after the initial exacerbation, 5, 9, 30, 31 possibly due to ongoing lung and systemic inflammation. 32 While acquisition of new strains of respiratory pathogens is an important mechanism underlying acute COPD exacerbations, 33 chronic microbial colonisation of the lower respiratory tract is also relevant. 34e36 This colonisation is likely to contribute to chronic inflammation and progressive loss of lung function in COPD due to increased rate of exacerbations. 33,35e39 Treatments aimed at reducing bacterial colonisation, which may be regarded as chronic infection in the presence of an inflammatory response, 40 may, therefore, help reduce the progression of the disease. It is also likely that the chronic inflammation in COPD compromises innate lung defence, increasing susceptibility to acute infection and thus the risk of subsequent exacerbations. Identifying the sub-group of COPD patients who are subject to this vicious cycle of chronic inflammation and infection is challenging, though infection is signalled by the presence of chronic purulent sputum production. High resolution CT scan may help identify bronchiectasis, particularly in the presence of Pseudomonas aeruginosa. 41e43 In the future, sputum biomarkers might help in management. 44 Traditionally, most antibiotic clinical trials have focussed on short-term clinical efficacy in the treatment of AE-COPD. Recently, information has emerged on the longer-term outcomes of acute treatment for an exacerbation (i.e. several weeks or months after initial antimicrobial treatment), and on the possible value of long-term antibiotic therapy as a longer-term strategy to prevent future exacerbations. 45, 46 This article reviews the current evidence on the impact of acute antibiotic treatment on the long-term outcomes in COPD, explores the potential for the use of prophylactic antibiotics and discusses the possible role of inhaled antibiotics in patients with the condition.
Impact of acute antibiotic treatment on longterm outcome in AE-COPD have been two recent placebo-controlled trials of antibiotics in AE-COPD. 26, 27 In one study, addition of 7-day doxycycline treatment to systemic corticosteroids in patients hospitalised with AE-COPD, showed limited benefit from the antibiotic treatment. The primary clinical endpoint of clinical success on Day 30 was not met (61% vs 53%; odds ratio [OR] 1.3; P Z 0.32), with the two arms also being equivalent for clinical cure at Day 30. 26 Although doxycycline was found to be superior to placebo in terms of clinical success (OR 1.9; P Z 0.03) and clinical cure (OR 1.9; P Z 0.01) on Day 10 of the study, 26 such treatment had no effect on lung function or systemic inflammation (measured by change in FEV 1 and serum C-reactive protein, respectively, at Days 10 or 30). The authors concluded that failure of the primary outcome may have been due to the use of steroids, which may have limited the benefit of antibiotics in this study. Alternatively, the lack of effect may have been due to insufficient antibacterial activity of doxycycline; indeed, the rate of bacteriological eradication of the offending pathogen in this study was only 67% with doxycycline versus 34% with placebo, which could explain the lack of durability of the clinical efficacy. Llor et al. 27 in an outpatient study of the efficacy of antibiotics in acute exacerbation of mild-to-moderate COPD demonstrated that amoxicillinclavulanate is associated with greater clinical success compared to placebo at the end-of-therapy visit (Days 9e11) for those with Anthonisen type II criteria (74.1% vs 59.9%, respectively; 95% CI of the difference in percentage of success 3.7e24.3%). This study showed that there are clear short-term benefits from antibiotics in an outpatient setting in patients without severe disease. 27 Based on these and previous studies, the short-term benefit in terms of clinical cure or success of about 13e15% above placebo is seen with antibiotic use. Interestingly, this magnitude of benefit is very similar to what is seen with systemic steroid use at exacerbation. Few studies have addressed whether antibiotic treatments have any enduring effects. This is due to the fact that most antibiotic studies only include follow up for up to 21 days after the end-oftreatment.
49e54 These follow-up periods are likely to be far too short to identify all relapses, since risk of relapse is highest in the 8-week period after the end-of-therapy. 30 The effect of a single course of acute antibiotic treatment on longer-term outcomes has been examined in some studies, with patients being followed for between 8 weeks and 1 year. 27,28,31,55e61 Only one of these studies 27 was placebo controlled, while the remainder were antibiotic comparison trials. In the placebo-controlled trial by Llor et al. discussed above, amoxicillin/clavulanate was associated with a significantly prolonged time to the next exacerbation during the long-term follow-up period (233 days vs 160 days; P < 0.05). 27 The antibiotic comparison trials are important also, as they demonstrate that antibiotic choice impacts on long-term outcomes in AE-COPD, specifically reducing clinical relapses, the need for additional antibiotics and prolonging the time to the next exacerbation. However, not all studies demonstrated differences in long-term outcomes between antibiotic treatments. Antibiotic comparison trials where long-term outcomes of exacerbations were examined are summarised in Table 1. Comparison between these trials is difficult due to the fact that some enrolled patients with AE-COPD, while others involved patients with exacerbations of chronic bronchitis; patients included may, therefore, reflect different inflammatory sub-phenotypes and varying severity of airflow obstruction within COPD. 62 The endpoints employed and the demographic characteristics of the study populations also varied between studies. For example, in the study reporting the longest follow-up period of one year, patients receiving antibiotic treatment with either levofloxacin or clarithromycin experienced a mean exacerbation-free interval of more than 300 days. 59 In a further study employing a 6-month follow-up, antibiotic treatment with levofloxacin or clarithromycin led to an infection-free interval of 112 and 102 days, respectively. 58 The difference in exacerbation-free interval resulting from levofloxacin treatment in these two studies (300 days vs 112 days) is unclear, but may be due to the fact that 82% of patients in the latter study had severe or very severe COPD (forced expiratory volume in 1 s [FEV 1 ] < 50% predicted), 58 in contrast to only 27% of severe patients in the former study. 59 The pioneering trial in this field by Chodosh et al. 60 demonstrated that ciprofloxacin achieved higher bacteriological eradication rates than clarithromycin, however, with a non-significant increase in the infection-free interval associated with ciprofloxacin (142 vs 51 days, P Z 0.15). The MOSAIC trial, a large study enrolling patients with stable COPD prior to an acute exacerbation, showed significant improvement in long-term outcomes with moxifloxacin during a 9-month follow-up period versus standard antibiotics (amoxicillin, clarithromycin or cefuroxime-axetil) 55 reporting delayed onset of a composite failure event (treatment failure and/or new exacerbation and/or any further antibiotic treatment). In two other studies, gemifloxacin was associated with significantly lower relapse rates in 6 months, non-significant reduction in hospitalisations (P Z 0.059) and better health status scores at 6 months than clarithromycin. 9, 31 A smaller study, conducted by Nouira et al., was not able to show any difference in long-term outcomes in hospitalised patients between ciprofloxacin and trimethoprim-sulfamethoxazole. 61 In the recently published MAESTRAL study, while moxifloxacin treatment was comparable to amoxicillin/clavulanic acid for the primary endpoint of clinical failure at 8-weeks post-therapy, moxifloxacin resulted in significantly lower clinical failure and higher bacteriological eradication in a sub-population of patients with bacterial pathogens isolated from sputum at the time of exacerbation. 28 The exact mechanism(s) underlying the effects of acute antibiotic treatment on long-term outcome is (are) uncertain, though eradication of the infecting bacteria causing the exacerbation is likely to play a key role. This was best demonstrated in the MAESTRAL study, in which in the posthoc assessment of a sub-group of patients with bacterial pathogens isolated from sputum at the time of exacerbation, a significant relationship was observed between bacterial eradication at end-of-treatment (EOT) and the rate of clinical cure at 8 weeks. This relationship was seen both in the overall population and in moxifloxacin-treated patients, though the correlation was not present in those treated with amoxicillin/clavulanic acid. 28 Interestingly, the studies that have shown significant differences between the fluoroquinolones and the comparators in long-term outcomes have been conducted with agents Antibiotics for treatment and prevention of AE-COPD (moxifloxacin and gemifloxacin) that have better activity against Gram-positive pathogens such as Streptococcus pneumoniae. In contrast, initial studies with ciprofloxacin and low-dose levofloxacin have not been able to show improvement in long-term outcomes. While the increased airway inflammation present during an acute exacerbation is thought to be reduced following antibiotic treatment, 63e66 this improvement may be dependent on bacterial eradication. 25 Such incomplete resolution of the initial exacerbation and persistent bacterial infection appear to be important determinants of the risk of relapse.
23e26,37
Overview of clinical trials of prophylactic antimicrobial use in AE-COPD
The concept of long-term antibiotic use comes from a number of other chronic respiratory tract conditions in which chronic bacterial infection occurs. The wellestablished indication for the long-term use of inhaled antibiotics is the prevention of exacerbations in cystic fibrosis patients, 67e71 and more recently in non-cystic fibrosis bronchiectasis. 72 Long-term macrolide therapy was first shown to be of significant benefit in a predominantly Japanese respiratory disease, diffuse pan-bronchiolitis. 73 Though less well established long-term treatment with low-dose erythromycin or clarithromycin has also been shown to improve clinical outcome in patients with intractable chronic sinusitis. 74, 75 In non-cystic fibrosis bronchiectasis, addition of twice-weekly azithromycin to patients' usual medications for 6 months significantly decreased the incidence of exacerbation and 24-h sputum volume. 76 Furthermore, long-term, low-dose erythromycin has been shown to be effective in bronchiectasis subjects with frequent infective exacerbations. 77 More recently, 6-month treatment with azithromycin reduced the frequency of exacerbations in bronchiectasis patients with a history of at least one exacerbation in the previous year, though no improvement in quality of life was observed during the treatment period. 78 The potential role of long-term antibiotic therapy in the management of COPD was first investigated in the 1950s and 1960s. However, these studies were limited by small patient numbers, use of low doses of narrow-spectrum antibiotics and poor efficacy measurements. Concerns regarding resistance also hindered further investigation into the value of this approach. 79 Nonetheless, new antibiotic formulations with improved antibacterial activity coupled with better understanding of the pathogenesis of COPD has led to renewed interest in the role of long-term antibiotic use in COPD management, 80 though no agents are currently licensed for such therapy.
Review of more recent reports from the last decade investigating the long-term use of antibiotic treatment in COPD patients revealed a total of seven studies examining continuous therapy 45,81e86 and one employing an intermittent/pulsed schedule ( Table 2) . 46 Of the studies investigating continuous therapy, all investigated long-term macrolide therapy, with most examining treatment over a 12-month period. 45, 81, 86 The rationale for the use of macrolides as maintenance therapy stems from the fact that these agents hold immunomodulatory and anti-inflammatory effects in addition to their antibacterial properties. 87 In the first 12-month study, erythromycin therapy was found to have beneficial effects on the prevention of exacerbations in 55 COPD patients. 81 The proportion of patients with one or more episodes of exacerbation during the treatment period was lower in patients treated with erythromycin (11%) compared to the controls (56%), and significantly more control patients than erythromycin patients were hospitalised due to exacerbations (P Z 0.0007). It should be noted, however, that this investigation was limited in that it was an open-label study, not a randomised double-blind placebo-controlled trial. Such a trial of erythromycin treatment was subsequently shown to significantly reduce exacerbation frequency and median time to exacerbation in a 12-month study, though no differences between arms were observed in FEV 1 or inflammatory markers. 86 In contrast, no reduction of exacerbations, sputum neutrophil numbers or cytokine levels were observed following 3-month treatment with clarithromycin versus placebo, possibly due to the small sample size (n Z 67) and shorter study period. 82 However, significant reductions in inflammatory markers and neutrophil counts were reported following 6-month treatment with azithromycin in addition to standard care in severe COPD patients 83 and with erythromycin versus placebo, respectively. 84 Recently, in a large definitive study, Albert et al. 45 have investigated the use of 12-month treatment with daily azithromycin in COPD patients with an increased risk of exacerbations (mean age 65 years, FEV 1 % predicted was 39%). In this study, addition of azithromycin to standard therapy led to a 27% decrease in the frequency of exacerbations, an increase in the median time to exacerbations (266 days vs 174 days, respectively; P < 0.001) and significantly improved disease specific health status (St George's Respiratory Questionnaire [SGRQ] À2.8 vs À0.6; P Z 0.004). However, the improvement in the SGRQ did not reach the minimal clinically important difference. Azithromycin was also shown to reduce exacerbations, hospitalisations, and length of hospital stay in patients with severe COPD (mean age 71 years, FEV 1 % predicted 32%, 7.0 exacerbations in previous year) in a 12-month retrospective study. 85 The effect of azithromycin in this study was particularly marked in patients with common potentially pathogenic microorganisms isolated in sputum (i.e. Haemophilus influenzae, S. pneumoniae or Moraxella catarrhalis), reducing exacerbations and hospitalisations by 70% and mean hospital stay by 25 days.
Intermittent, pulsed fluoroquinolone antibiotic therapy in COPD patients has been investigated in a study conducted by Sethi et al. 46 In this study, moxifloxacin was administered once daily for 5 days, with treatment being repeated every 8 weeks for a total of six courses. 46 The rationale for pulsed therapy was mainly driven by the concerns about the emergence of resistance with long-term continuous use of antibiotics. Pulsed therapy would allow time for the normal flora to recover and therefore potentially prevent or delay the emergence of resistant strains. 33 Moxifloxacin was selected for the study based on its potent in vitro activity against the major COPD pathogens, excellent penetration into respiratory tissues, high oral bioavailability and proven efficacy in increasing the Antibiotics for treatment and prevention of AE-COPD Antibiotics for treatment and prevention of AE-COPD exacerbation-free interval. 46, 55, 88 Pulsed therapy with moxifloxacin was found to significantly reduce the risk of an exacerbation by 25% (per protocol population) in patients with moderate-to-severe COPD, while in a post-hoc analysis, this reduction was 45% in patients with purulent/mucopurulent sputum at randomisation. 46 These studies suggest that long-term antibiotic treatment in COPD patients reduces exacerbation frequency, though evidence for a reduction in inflammation is limited. Long-term antibiotic therapy appears to be well tolerated, though not all studies reported safety. 81 Nevertheless, gastrointestinal events were more common in patients receiving pulsed moxifloxacin versus placebo (4.7% vs 0.7%, respectively) 46 and 12-month azithromycin treatment resulted in a higher incidence of hearing loss (25% of patients with azithromycin vs 20% of patients with placebo). 45 Although long-term (daily) azithromycin treatment led to a decrease in the incidence of colonisation by respiratory pathogens, such treatment was also associated with an increased prevalence of macrolide-resistant bacteria colonising the airways, though there was no evidence that this colonisation increased the number of exacerbations or the incidence of pneumonia. 45 No relevant resistance was reported in the study with pulsed (with one cycle lasting for only 5 days in every 8 weeks) moxifloxacin treatment, 46 while in others resistance development was minimal 85, 86 or not reported. 81, 82 Although the studies described above suggest that use of prophylactic oral antibiotic therapy is well tolerated, some macrolides are known to be proarrhythmic and even 5-day treatment with azithromycin has been associated with a small absolute increase in cardiovascular deaths. 89 This issue, coupled with concerns of increased antibiotic resistance, indicates that such treatment should be reserved for those with severe COPD who experience frequent exacerbations requiring multiple antibiotic treatments, in spite of adequate management of their COPD with standard treatments. 90 Future directions: the role of inhaled antibiotics in patients with COPD Use of inhaled antibiotics is expected to have a future role in the long-term management of patients with COPD since this route of administration has the ability to target drug delivery directly to respiratory tract. Such targeting reduces systemic exposure and maximizes pharmacodynamic parameters, thereby also likely reducing the emergence of antibiotic resistance and minimizing the development of systemic adverse effects. Inhaled antibiotics have already been used in the treatment of other respiratory tract conditions, including cystic fibrosis (CF) 67, 68 and bronchiectasis. 91, 92 Administration of aerosolised antibiotics plays a particularly important role in CF, since patients with the condition suffer from diminished mucociliary clearance, increasing their susceptibility to colonisation and infection by bacterial pathogens, including P. aeruginosa. 93 In this population, intermittent inhaled tobramycin has been shown to improve pulmonary function and decrease the density of P. aeruginosa in sputum, leading to significant reductions in respiratory hospitalisations. 67, 68 Inhaled gentamycin has recently been shown to have a beneficial effect on outcomes in bronchiectasis, reducing the number of exacerbations and decreasing P. aeruginosa in the sputum. 72 In addition, use of inhaled dry powder ciprofloxacin in bronchiectasis patients has been associated with improved quality of life, which is likely to be due to reductions in bacterial load and improved eradication (of approximately 35%). 91 Inhaled antibiotics appear to be well tolerated in most of the above studies, reducing the risks of adverse effects associated with systemic exposure. While wheezing and localised irritation (e.g. cough, bronchospasm) have been reported in some studies, 92, 94, 95 most report minimal side effects. 67, 68, 91 Choice of antimicrobial is dependent on pharmacokinetics/pharmacodynamics in the bronchopulmonary tree, with the ability to achieve high C max values favouring concentration-killing drugs, while the applied delivery system influences particle size distribution and hence deposition and exposure. 96, 97 Although the optimal dosing regimen (e.g. continuous or pulsed) for inhaled antibiotics in COPD has not been determined, their administration in aerosolised form has the ability to achieve high, microbiologically relevant concentrations in respiratory secretions in excess of the MIC of the infecting organism(s). 98 In COPD patients with chronic bacterial infection, delivery of a high concentration of antibiotic in the airway through inhalation may lead to a reduction in chronic inflammation via a reduction in bacterial load, potentially reducing the frequency of exacerbations. Nevertheless, evidence for a reduction in airway inflammation following the use of aerosolised antibiotics is limited.
The pharmacodynamic/pharmacokinetic profile of inhaled antibiotic therapy in the lower respiratory tract are quite different from systemic antibiotic use. The measured concentrations of various antibiotics (gentamycin, sisomycin, amikacin, tobramycin) in various locations in the respiratory tract following inhalation exceeded the highest MICs of the prevalent pathogens by between 50 and 125 times. 99e105 In the presence of such high concentration of antibiotics the density of pathogens was reduced in the sputum or the pathogens were completely eradicated (Table 3) . 67,91,106e116 However, adequate delivery of antibiotic to the airways through inhalation is a complex method influenced by several factors. Conditions that have to be optimised include the choice of nebuliser (jet or ultrasonic, vibrating mesh inhaler), the drug formulation (aerosolised solution or dry powder), the particle size (must be between 1 mm and 5 mm for adequate deposition and delivery into lower airways), the chemical properties of the molecule (e.g. lipophilic or hydrophilic). Furthermore, patient characteristics including age and lung function, the respiratory cycle length and inspiratory/expiratory ratio, may also influence efficiency of inhaled antibiotic delivery.
As seen with long-term systemic antibiotic use, concern exists too for inhaled antibiotics regarding the possibility of resistance development during long-term treatment. As shown in Table 3 , there is inconsistent evidence for the emergence of resistant pathogens during treatment with aerosolised antibiotics in some respiratory conditions 67, 95 ( Table 3) . It is likely that risk of resistance development may be lessened by use of shorter courses, intermittent therapy (as currently practiced in cystic fibrosis) or alternating different antibiotic classes.
Antibiotics for treatment and prevention of AE-COPD Antibiotics for treatment and prevention of AE-COPD To date, there have been only two published reports investigating the use of inhaled antibiotics in patients with COPD. Dal Negro et al. 117 examined the impacts of 14-day, twice daily treatment with inhaled tobramycin nebuliser solution on clinical outcome as well as inflammatory markers in bronchial secretions from a small cohort (n Z 13) of multiresistant P. aeruginosa-colonised patients with severe COPD (FEV 1 < 50% predicted). P. aeruginosa infection is associated with a severe degree of functional impairment in COPD, 118 and colonisation could well herald the presence of bronchiectasis, 41, 119 suggesting a potential role for inhaled antibiotics. Indeed, such treatment resulted in a substantial reduction from baseline of pro-inflammatory chemotactic mediators, including interleukin-1 beta (P < 0.03), interleukin-8 (P < 0.02) and eosinophilic cationic protein (P < 0.01). After the 6-month follow-up period, P. aeruginosa was considered to be eradicated in two patients, while P. aeruginosa density was reduced in a further four patients. Two-week treatment with inhaled tobramycin decreased the frequency of exacerbations by 42%, when compared with the 6-month period prior to initiating inhaled tobramycin therapy. 117 Although this study has many limitations, including its open-label design and its small size, it does suggest a therapeutic role for inhaled antibiotics in COPD patients, particularly those colonised with multiresistant P. aeruginosa. Nevertheless, a recent phase II study investigating the efficacy of MP-376 (levofloxacin inhaled solution) in COPD patients at high risk for exacerbations (n Z 322) failed to demonstrate a significant reduction in the exacerbation rate or an increase in the time to the next exacerbation compared with placebo. 120 However, the treatment duration employed in this study (5 days every 28 days for 9e12 cycles) may have been suboptimal in a population of patients with chronic infection. 121 Ongoing and future trials will inform us if inhaled antibiotics are a useful therapeutic option in the prevention of exacerbations of COPD.
Conclusions
Acute, efficacious antibiotic treatment is the mainstay in the management of patients with severe COPD and symptomatic exacerbations that include at least 2 of the 3 cardinal symptoms (increased sputum purulence, volume and increased dyspnoea; Anthonisen type I or II exacerbations). Although such treatment is associated with clinical benefit, treatment failure and relapse rates may be high in patients with the frequent exacerbator phenotype. Failure may be related to inadequate antibiotic efficacy through incomplete resolution of the initial exacerbation and persistent bacterial infection.
23e26 These factors have led to recommendations for a stratified approach to antibiotic therapy based on patient risk factors. 15 Patients at greatest risk for poorer outcome (i.e. those with complicated COPD) are likely to derive greatest benefit from early treatment with the most potent antibiotic therapy, such as amoxicillin/clavulanate and respiratory fluoroquinolones which have a broad spectrum of activity against likely pathogens. 28,122e124 The use of the most efficacious antibiotics in patients with risk factors may be crucial in preventing relapses or delaying subsequent exacerbations which appear to cluster in time, and if the exacerbation is poorly controlled there is a high risk of the next episode occurring within a few weeks. 30 A significant relationship exists between bacterial eradication at the end of antibiotic treatment and no relapse in the following eight weeks. 28 Studies conducted in the last 20 years suggest that longterm or intermittent antibiotic therapy may have a beneficial effect on the outcome of COPD patients and may improve quality of life by reducing exacerbation frequency and hospitalisations for exacerbations, or by extending time to next exacerbation. The mechanisms underlying such improvements are unclear. It is possible that the benefit of long-term antibiotic treatment may be due to a reduction in the frequency of exacerbations due to eradication of colonising potentially pathogenic bacteria and/or reduction in chronic airway inflammation, 37 though the evidence supporting such a hypothesis is limited. While macrolides are known to have both antibacterial and antiinflammatory effects, it is unknown to what degree these actions are responsible for their efficacy when used for the treatment of chronic respiratory conditions. The increased rate of nasopharyngeal colonisation by pathogens resistant to macrolides seen following long-term azithromycin therapy 45 suggests that emergence of antibiotic resistance is likely with this approach.
Although systemic antibiotics are likely to remain the primary treatment option for patients with moderate-tosevere COPD, inhaled antibiotics may provide a more appropriate way for the treatment and prevention of exacerbations in the future, particularly for the frequent exacerbators with chronic bacterial infection and for those with radiologically confirmed bronchiectasis. Regardless of the route of administration, however, further studies are required to estimate the potential risks of antibiotic prophylaxis in terms of long-term adverse events and resistance development and to assess whether benefit outweighs the potential risks. 
